CORONA Remedies Limited, (formerly known as CORONA Remedies Private Limited) has launched its generic
version of Empagliflozin introduced under the brand name “Empabite & it extensions” a SGLT-2 inhibitor, for
Type 2 diabetes. With a commitment to affordability and accessibility, CORONA Remedies will offer the
medication at a significantly reduced price, making it more accessible to patients.
Empagliflozin works by blocking the sodium-glucose co-transporter 2 (SGLT2) in the kidneys. This increases the
amount of glucose that is excreted in the urine, which lowers blood glucose levels. Beyond Glucose lowering
property, Empagliflozin can delay Chronic Kidney Disease (CKD) and Heart failure progression in patients with
or without Diabetes 1 .
Commenting on the launch, Mr. Nirav Mehta, CEO & Managing Director of CORONA Remedies, stated, “At
CORONA Remedies, our vision has always been ‘One world, one quality.’ We are committed to making essential
medicines, affordable without compromising on global standards. We believe, the launch of our Empagliflozin,
will empower many Indian patients, with access to advanced diabetes care at a reduced cost. This reinforces our
dedication to public health and our mission to provide quality treatment at an affordable price.”
About CORONA Remedies Limited
CORONA Remedies Limited was founded in 2004 and is headquartered in Ahmedabad, India. The company as
per Indian Pharmaceutical Market is ranked 29 (in terms of MAT Feb’25 source: PharmaTrack) and specializes
in women’s healthcare, cardio-diabetic, pain management and other therapeutic areas. Its manufacturing
facilities in Ahmedabad and Solan, meets the global regulatory standards, including WHO-GMP, EU-GMP
supporting a broad distribution network across India
CORONA Remedies is committed to ethical, transparent, and innovative practices. The company delivers
evidence-based products, aiming to make healthcare more accessible and improve patient outcomes in the
markets it serves.
For more information, visit https://www.coronaremedies.com/. Stay updated with the company’s latest
developments on LinkedIn (CORONA Remedies Limited) and Instagram (coronaremedies).
For further enquiries, please contact:
Ms. Tasneem Savliwala | Tasneem.savliwala@adfactorspr.com | +91 8850291322
Mr. Dhairya Chheda | dhairya.chheda@adfactorspr.com | +91 9619280205
